In response to the global COVID-19 pandemic, Beckman Coulter, a global leader in clinical diagnostics, announced 31 March that it is developing assays to identify IgM and IgG antibodies to SARS-CoV-2. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body\u2019s immune system to produce antibodies that can be detected with IgM and IgG tests.
\nThe assays will be designed for use on any of Beckman Coulter\u2019s high-throughput Access family of immunoassay systems, including the Access 2 and DxI series, which can be found worldwide.
\n\u201cAntibody assays play a critical role in understanding the level of immunity an individual has developed against SARS-CoV-2,\u201d said Kathleen Orland, Senior Vice President and General Manager for Beckman Coulter\u2019s Chemistry and Immunoassay Business. \u201cThis type of understanding could help identify those who would require a vaccine, once available, or when an infected individual could safely return to work.\u201d
\nShamiram R. Feinglass, MD, MPH, Chief Medical Officer, Beckman Coulter, added: \u201cWith the ability to assess a patient\u2019s immunity to SARS-CoV-2, this testing modality may enable clinicians to clear hospital staff, emergency responders, and others to get back to work with an indication that they have had prior exposure and therefore have built an immunity to the disease. This test could allow those without immunity to be identified and kept safe until the pandemic subsides.\u201d
\nBeckman Coulter operates within the Danaher Corporation, together with a collection of the world\u2019s leading diagnostic companies, all on the front line in the fight against coronavirus.
\nOnce the assays are finalized, Beckman Coulter intends to achieve CE mark certification and to follow FDA\u2019s Emergency Use Notification process.
\nFor the latest information on the new assays, visit www.beckmancoulter.com\/coronavirus<\/link>\n","protected":false},"excerpt":{"rendered":"
In response to the global COVID-19 pandemic, Beckman Coulter, a global leader in clinical diagnostics, announced 31 March that it is developing assays to identify IgM and IgG antibodies to SARS-CoV-2. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body\u2019s immune system to produce antibodies that can be detected with IgM […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[36,35],"tags":[],"class_list":["post-690","post","type-post","status-publish","format-standard","hentry","category-corona-news","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/690"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=690"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/690\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}